An interventional study of Transcutaneous Electrical Nerve Stimulation (TENS) in Breast Feeding, sponsored by Holy Family Hospital, Nazareth, Israel. Recruiting at 2 sites in Israel. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Holy Family Hospital, Nazareth, Israel · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Breast Feeding with a site in Israel — 4 open to participants now, 4 under way, none of them phase 3. Breast Feeding · Israel.
Among the 21 studies in Breast Feeding with a site in Israel, this one is the 6th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 21st registered.
1,083 studies on the registry are indexed under Breast Feeding; 218 are open to participants now.
Browse Breast Feeding studies →4 of the 21 studies in Breast Feeding with a site in Israel are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Israel, United States, Canada and 4 more countries
Ages 3 wk+ · Women only
Bar-Ilan University, Israel · Sites in Israel
Ages 20–40 · Women only · Healthy volunteers
Assaf-Harofeh Medical Center · Sites in Israel
Ages 18–55 · Women only · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 100 across 846 interventional studies indexed under Breast Feeding.
Median enrollment 60 across the 15 interventional studies, 100 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 21 have an industry lead sponsor. The 10 most frequent:
Holy Family Hospital, Nazareth, Israel is the lead sponsor of 10 studies on the registry; 9 are open to participants now.
Holy Family Hospital, Nazareth, Israel has 1 study filed under Breast Feeding — fewer than ten, so there is no comparison to draw.
1 of the studies in Breast Feeding with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703917Holy Family Hospital, Nazareth, IsraelTENS for Postpartum Uterine Pain During Breastfeeding | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Breast Feeding with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study is designed to evaluate whether Transcutaneous Electrical Nerve Stimulation (TENS) is an effective, non-drug method to relieve postpartum uterine pain during breastfeeding in multiparous women (women who have given birth multiple times). Breastfeeding in the first 48 hours after delivery often triggers strong, painful uterine contractions due to the natural release of oxytocin. While standard care typically relies on pain-relief medications, this study investigates if TENS, a safe, low-cost device that sends gentle electrical impulses through small skin patches, can significantly reduce this pain and decrease the need for systemic medications. Participants will be randomly assigned to either receive standard postpartum pain medications or use a TENS device during two consecutive breastfeeding sessions. Researchers will measure and compare the peak pain levels between both groups using a standard 0 to 10 pain scale. The aim is examining whether TENS will significantly reduce postpartum uterine pain during breastfeeding and decrease medication use compared with standard care.
This randomized, controlled, parallel-group clinical trial will evaluate the efficacy and safety of Transcutaneous Electrical Nerve Stimulation (TENS) as a non-pharmacological intervention for reducing oxytocin-induced postpartum uterine contractions during breastfeeding. The study cohort consists of 124 eligible multiparous women (2 or more previous births) admitted to the Department of Obstetrics and Gynecology at Holy Family Hospital in Nazareth, Israel, within 48 hours following a term, singleton, vaginal delivery. Following the acquisition of written informed consent, participants will be randomized at a 1:1 ratio into either the TENS study group or the standard care control group. The experimental protocol will be integrated into two consecutive breastfeeding sessions. Body positioning will be strictly standardized across both cohorts. TENS Study Group (Intervention): Prior to the second consecutive breastfeeding session, four conductive gel electrodes will be affixed to the participant. Two electrodes will be positioned bilaterally over the lower abdomen, directly overlying the uterus. The remaining two electrodes will be placed in parallel in the S2-S4 dermatomal region to target the spinal nerve pathways receiving nociceptive afferent input from the uterus and cervix. Active stimulation will commence a few minutes prior to breastfeeding and continue for the entire duration of the feed. The TENS device will deliver 80-Hz current and 200 msec pulse for 40 min, using 20-40 milliamps of intensity.
To establish a baseline pain score, the first evaluated breastfeeding session for this group will be conducted without TENS application, followed by active TENS during the second session. Control Group Protocol: Participants assigned to the control group will receive standard postpartum care and will undergo the identical data collection schedule across two consecutive breastfeeding sessions, but without any TENS electrode placement or electrical stimulation.
For both study arms, pharmacological analgesia will remain accessible as needed per existing institutional department protocols, and all instances of medication administration (including specific agent, timing, and dosage) will be precisely documented. Uterine pain scores will be captured across both groups at three identical time points during each of the two consecutive breastfeeding sessions: Maternal discomfort associated directly with the physical application or sensation of the TENS unit will be separately quantified.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm is receiving the active clinical intervention being evaluated in the study (the TENS device). Pain scores will be assessed during two consecutive breastfeeding sessions. The first with, and the second without TENS.
Device: Transcutaneous Electrical Nerve Stimulation (TENS)
Participants assigned to this control group will receive standard postpartum care only, without any TENS application. Pain scores will be assessed during two consecutive breastfeeding sessions within the first 48 hours postpartum to serve as a comparative baseline against the intervention group.
Bilateral application of four skin electrodes using conductive gel. Two electrodes will be placed on the lower abdomen over the uterus, and two will be placed in parallel in the S2-S4 sacral region. The digital sensory-motor TENS device will be programmed to generate 80-Hz current and 200 msec pulse for 40 min, using 20-40 mA of intensity. Stimulation begins a few minutes before breastfeeding and continues throughout the 40-minute session.
Peak VAS pain score during breastfeeding in the second session
The maximum VAS score recorded will be compared between groups. Postpartum uterine pain during breastfeeding will be evaluated using a standard Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Time frame: During the second breastfeeding session, within the first 48 hours postpartum
Consumption of Pharmacological Analgesics
Total dosage (mg) of pain relief medications consumed by the participant within the first 48 hours postpartum.
Time frame: First 48 hours postpartum
Peak VAS pain score during breastfeeding in the second compared with the first sessions.
The maximum VAS score in the first and second session will be recorded and compared within the same group. Postpartum uterine pain during breastfeeding will be evaluated using a standard Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Time frame: During two consecutive breastfeeding sessions within the first 48 hours postpartum
Duration of breastfeeding sessions.
The time, in minutes, that the woman is able to continue breastfeeding.
Time frame: In the two consecutive breastfeeding sessions within the first 48 hours postpartum
Adverse effects related to TENS use
Local adverse effects related to TENS in the intervention group.
Time frame: During the second session, within the first 48 hours postpartum
Maternal discomfort
The women will also be asked to estimate the discomfort of the TENS use using a 5-point verbal scale from no discomfort (0) to worst possible discomfort (5).
Time frame: First 48 hours postpartum
Formula use
Use of any infant formula in addition to breastfeeding
Time frame: First 48 hours postpartum
Plan to share: Yes — Individual patient data (IPD) that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After publication (starting 6 months after publication).
Access criteria: De-identified IPD will be available to academic or clinical researchers for meta-analyses, and research addressing questions related to the study topic. Requests must include a research protocol, statistical analysis plan, ethics approval, and details of the research team. Requests will be reviewed by the principal investigator. Data will be provided after approval and completion of a data-sharing agreement.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.
Of 504 non-industry interventional studies with no phase under Breast Feeding, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 10 months is below that.
Counting every sponsor, half of 512 studies reached it within 12 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Holy Family Hospital, Nazareth, Israel